New Drug Baxdrostat Shows Promise for Kidney Disease and Hypertension
September 6, 2025 — Baxdrostat Phase 2 trial shows 5% blood pressure reduction and 55% less urine albumin in chronic kidney disease patients. Novel aldosterone inhibitor may delay kidney disease progression.